Clinical analysis of anti-NR2 glutamate receptor antibodies and interleukin-6 with neuropsychiatric systemic lupus erythematosus
2011 ◽
Vol 50
(11)
◽
pp. 2142-2144
◽
S. Sato
◽
H. Kawashima
◽
A. Hoshika
◽
T. Yoshio
2008 ◽
Vol 58
(4)
◽
pp. 1130-1135
◽
Yoshiyuki Arinuma
◽
Tamiko Yanagida
◽
Shunsei Hirohata
2006 ◽
Vol 54
(2)
◽
pp. 675-678
◽
Taku Yoshio
◽
Koichi Onda
◽
Hiroyuki Nara
◽
Seiji Minota
Haruka Tsuchiya
◽
Yukiko Iwasaki
◽
Hirofumi Shoda
◽
Yukitoshi Takahashi
◽
Keishi Fujio
S Hirohata
◽
Y Matsueda
◽
T Yanagida
◽
T Yoshio
2010 ◽
Vol 36
(1)
◽
pp. 187-201
◽
Cynthia Aranow
◽
Betty Diamond
◽
Meggan Mackay
2017 ◽
Vol 12
(10)
◽
pp. e0186414
◽
Tomoyuki Asano
◽
Hiromi Ito
◽
Yoshinobu Kariya
◽
Kyoka Hoshi
◽
Akioh Yoshihara
◽
...
GLUTAMATE RECEPTOR ANTIBODIES IN NEUROLOGICAL DISEASES: Anti-AMPA-GluR3 antibodies, Anti-NMDA-NR1 antibodies, Anti-NMDA-NR2A/B antibodies, Anti-mGluR1 antibodies or Anti-mGluR5 antibodies are present in subpopulations of patients with either: Epilepsy, Encephalitis, Cerebellar Ataxia, Systemic Lupus Erythematosus (SLE) and Neuropsychiatric SLE, Sjogren’s syndrome, Schizophrenia, Mania or Stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor’s expression, impair glutamate-induced signaling and function, activate Blood Brain Barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and Ataxia in animal models, and can be removed or silenced in some patients by immunotherapy
2014 ◽
Vol 121
(8)
◽
pp. 1029-1075
◽
1999 ◽
Vol 42
(12)
◽
pp. 2729-2730
◽
Shunsei Hirohata
◽
Kinya Hayakawa
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 531.1-531
C.C. Mok
◽
K.L. Chan
◽
B. Diamond
2008 ◽
Vol 58
(1)
◽
pp. 1
◽
Kyu Chan Oh
◽
Woo Mok Byun
◽
Han Won Jang
◽
Kum Rae Kim